Clinical Trial Update: Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating re-induction of a systemic immune response in metastatic or locally recurrent lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Snippet

Sponsor: Maastricht Radiation Oncology | Conditions: Lung Cancer Stage IV | Phase 2 | Status: WITHDRAWN